Holy Stone Healthcare Company Description
Holy Stone Healthcare Co., Ltd. develops and sells hyaluronic acid-related therapeutic products in Taiwan.
The company offers RenehaVis, a product designed to relive pain and stiffness of the knee joint; SportVis, a treatment to relive the pain and optimize the recovery of tendon and ligament injuries; TRUD, a treatment that allows mucosal tissue to heal naturally and reduces the symptoms of ulcerative colitis; and GAF, a treatment for anal mucosal lesions.
It is also developing IBD98-M, which is in Phase II a clinical trials for the treatment of inflammatory bowel diseases; and CA102N to treat colorectal cancer.
In addition, the company develops ND108E for the treatment of alzheimer’s disease; AMD112 is a non-invasive HA-conjugated small molecule therapy; and HylCary, is a hyaluronic acid (HA) derived nanoparticle.
Holy Stone Healthcare Co., Ltd. was founded in 2001 and is headquartered in Taipei, Taiwan.
| Country | Taiwan |
| Founded | 2001 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Raymond Yang |
Contact Details
Address: No. 88, Neihu Road Taipei, 11493 Taiwan | |
| Phone | 886 2 8797 5966 |
| Website | hshc.com.tw |
Stock Details
| Ticker Symbol | 4194 |
| Exchange | Taipei Exchange |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| ISIN Number | TW0004194006 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Raymond Yang | Chief Executive Officer |
| Bill Tang | President |
| Yuling Liu | Accounting Supervisor |
| Charles Hou | Chief Scientific Officer |
| Dr. M. Sherry Ku Ph.D. | Chief Scientific Advisor |